Altered Long Noncoding RNA Expression Profile in Multiple Myeloma Patients with Bisphosphonate-Induced Osteonecrosis of the Jaw

Table 1

Number of controls and patients and clinical features of the examined disease.

Group	No. of patients (males, females)	Age (years)	Area with BONJ	BP treatment (yes/no (duration))	Durie–Salmon disease stage (no. of patients)	Median plasmocytosis (range)	Ig class
CTRL	8 (4 M, 4 F)		N/A	No	N/A	N/A	N/A
MM	8 (5 M, 3 F)		N/A	Yes (>1 year)	II (5); III (3)	65% (51–89%)	IgG
BONJ	8 (3 M, 5 F)		Mandible (5 patients); Maxilla (3 patients)	Yes (>1 year)	II (4); III (4)	74% (56–95%)	IgG

CTRL: control group; MM: multiple myeloma patients without bisphosphonate-induced osteonecrosis of the jaw; MM+BONJ: multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw; BP: bisphosphonates.